quite interesting about SinthRX ancquisition and Dr. Emanuele.
" We could issue up to an aggregate of 12,478,050 additional shares of our common stock to the former SynthRx stockholders if and when the development of vepoloxamer achieves certain milestones, with 3,839,400 shares issuable upon the U.S. Food and Drug Administration’s acceptance for review of a new drug application covering the use of vepoloxamer for the treatment of sickle cell crisis in children, which we refer to as the Second Milestone, and 8,638,650 shares issuable upon approval of such new drug application by the FDA, which we refer to as the Third Milestone. Dr. Emanuele would receive approximately 21% of the shares issuable in connection with achievement of the Second Milestone and the Third Milestone."
Emanuele will receive 2.6 milion shares on approval
....Sabby Management and Mr. Mintz do not directly own any shares, but each has shared power to vote or to direct the vote and shared power to dispose or to direct the disposition of 19,251,250 shares of our common stock, 6.69% of which is owned by Sabby Healthcare Master Fund, Ltd. and 3.30% is owned by Sabby Volatility Warrant Master Fund, Ltd. Sabby Management is the investment manager of Sabby Healthcare Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. and Mr. Mintz is manager of Sabby Management.
read the notes:
(4) Consists of (a) 3,721,786 shares of common stock subject to options currently exercisable or exercisable within 60 days of the Evaluation Date and (b) 34,500 shares of common stock held directly by Mr. Culley.
He has 34,500 shares and 3,7 million options
I said this because years ago I went through 2 cases of a very odd behavior of the pps the days around a big news,both were small cap biotech waiting long time for binary news, one went down from 0.25 to 0.10 in some months and bottomed the day before the FDA clearance(up 600%) another went up 70% the day before bad news.
I learned that nothing is really sure before a readout because smart and big money could know something in advance,and consequently try to maximize their gain, buying lower or shorting higher.
Just my opinion
IMO Mast now is only following the biotech sector, comparing the trend of IBB and MSTX after the last Mast' PO it's clear that they have the same shape. furthermore the volume is always low and the stock reactions to the news are feeble, all signs that investors are idle,few purchases few sales,no real flux. The interested investors bought months or even years ago and are holding.
I'm not so worried, nothing is changed and I already saw something like this years ago in a small biotech,the tiredness of the retailers permits the lowering of the pps.
A.Feuerstein demonstred in this 'article' to be totally incompetent about EPIC.
He only says something such as: ANX, previously failed,old news and only noise ...actually he knows nothing.
AF has been saying since 2011 or before that small bio trials,especially in oncology, have an high probability to fail (he reinvented the wheel !) and then he always bets against. Never an analysis, never a real DD.
Only a gamble method , don't worry and ignore him.
In the previous P2, as reported in Mast's presentations, the placebo duration was 80-88 hr, and for who received full dose was 80 vs 44 hr, or 45% reduction: an incredible result. Surely a P2 is less strict than P3, patients can be a bit influenced,but the difference is in any case very huge.
Previus P3 likely was designed differently,likely enrolling patients with more severe conditions and had some important flaws. Above all they truncated the duration at 168 and so cut off the long duration cases and losing a lot of additional hours in the placebo group,unbalancing the test from a statistical point of view. It is likely that 9 hr reduction was actually much higher with a correct measurement.
IMO the present trial is closer to P2 than P3,
not so recently. Also the previous trials, 18 years ago, were made with purified P188.
I think that the big pharma preferred own drugs formulas and they invested in biomolecuar or gene therapies drugs surely more actractive for the investors and for the capitalisation.
90% of these drugs failed specially if they were of the small cap.
would be very interesting testing several combos with Vepoloxamer . Some big pharma could find a good ally to reluanch failed or weak drugs .E.g. Eli Lilly prasugrel in SCD
is that poloxamer should have been already approved 20 years ago and it could have helped million patients in several deseases cardiovascular and neurological as well as scd.
Poloxamer is a perfect complementary drug safe and biologically restorative for cells and tissues , it is a therapy used alone but could be great and synergic in combo with other drugs.
you know my opion: for a company like Mast the sales prediction of Vepo is all.
How many hundred percent the pss will rise in a day , I don't know , surely there will a month very exciting with a turnover of investors and new TPs fixed from analysts, a revived company.
My personal PT for the week,or for the weeks of the results read out is around $3.